Tranexamic acid: A review of its use in the management of menorrhagia

Drugs

Volumn 63, Issue 13, 2003, Pages 1417-1433

  Wellington, Keri ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Antifibrinolytics; Heavy menstrual bleeding; Menorrhagia; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; CYKLO F; DANAZOL; DICLOFENAC; ETAMSYLATE; FLURBIPROFEN; HEMOSTATIC AGENT; LEVONORGESTREL; MEFENAMIC ACID; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; TRANEXAMIC ACID;

ABDOMINAL PAIN; ACNE; ALLERGY; AMENORRHEA; BACKACHE; BREAKTHROUGH BLEEDING; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL TRIAL; CONTRACEPTIVE DEVICE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE DURATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSMENORRHEA; DYSPEPSIA; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; IRON DEFICIENCY ANEMIA; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; LEG CRAMP; LUNG EMBOLISM; MENORRHAGIA; MENSTRUATION; MIGRAINE; MOOD DISORDER; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; PARESTHESIA; PELVIS PAIN SYNDROME; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; STATISTICAL SIGNIFICANCE; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS; URINARY FREQUENCY; VEIN OCCLUSION; VERTIGO; VOMITING; WEIGHT GAIN;

ANTIFIBRINOLYTIC AGENTS; CLINICAL TRIALS; FEMALE; HUMANS; MENORRHAGIA; TRANEXAMIC ACID;

EID: 0038121437     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363130-00008     Document Type: Review

References (59)

1. Merck & Co. I. Hemoatology and Oncology: hemostasis and coagulation disorders [online]. Available from URL: http://www.merk.com/pubs/mmanual/section11/chapter131/131b.htm [Accessed 2003 Feb 18]
2. Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with a single daily dose tranexamic acid. Haemophilia 1998 Jan; 4: 63-5
3. Woo YL, White B, Corbally R, et al. von Willebrand's disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002 Mar; 13 (2): 89-93
4. Gleeson NC. Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. Am J Obstet Gynecol 1994 Jul; 171 (1): 178-83
5. Ewenstein BM. The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding. Am J Obstet Gynecol 1996 Sep; 175 (3 Pt 2): 770-7
6. Cameron IT. Dysfunctional uterine bleeding. Baillieres Clin Obstet Gynaecol 1989 Jun; 3 (2): 315-27
7. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998 Feb 14; 351 (9101): 485-9
8. Dockeray CJ, Sheppard BL, Daly L, et al. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987 Apr; 24 (4): 309-18
9. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999 Jun; 57 (6): 1005-32
10. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation: influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975 May 30; 393 (1): 55-65
11. Anonick PK, Vasudevan J, Gonias SL. Antifibrinolytic activities of α-N-acetyl-L-lysine methyl ester, ε-aminocaproic acid, and tranexamic acid; importance of kringle interactions and active site inhibition. Arterioscler Thromb 1992 Jun; 12 (6): 708-16
12. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981 Feb 18; 673 (1): 75-85
13. Dubber AH, McNicol GP, Douglas AS, et al. Some properties of the antifibrinolytically active isomer of amino-methylcyclohexane carboxylic acid. Lancet 1964; II: 1317-9
14. Andersson L, Nilsson IM, Niléhn J-E, et al. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965; 2 (3): 230-47
15. Gleeson NC, Buggy F, Sheppard BL, et al. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994 Mar; 73 (3): 274-7
16. Shore-Lesserson L, Reich DL, Vela-Cantos F, et al. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg 1996 Jul; 83 (1): 18-26
17. Blauhut B, Harringer W, Bettelheim P, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994 Dec; 108 (6): 1083-91
18. Horrow JC, Van Riper DF, Strong MD, et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991 Nov; 84 (5): 2063-70
19. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg 1997 Nov; 85 (5): 963-70
20. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991 Oct; 38 (2): 113-9
21. Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res 1997 Feb 1; 85 (3): 195-206
22. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996 Nov; 85 (5): 1043-8; discussion 30A-31A
23. Menzies SA, Hartley JA, Hitchcock ER, et al. The effect of tranexamic acid on bleeding time and haemostasis. Neurochirurgia (Stuttg) 1991 Sep; 34: 141-3
24. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002 Aug; 97 (2): 390-9
25. Benoni G, Björkman S, Fredin H. Application of pharmacokinetic data from healthy volunteers for the prediction of plasma concentrations of tranexamic acid in surgical patients. Clin Drug Invest 1995 Nov; 10: 280-7
26. Eriksson O, Kjellman H, Pilbrant Å, et al. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol 1974 Aug 23; 7 (5): 375-80
27. Puigdellivol E, Carral ME, Moreno J, et al. Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol 1985 Jun; 23 (6): 298-301
28. Andersson L, Eriksson O, Hedlund P-O, et al. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 1978; 6 (2): 83-8
29. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981; 20 (1): 65-72
30. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP) opinion following an article 10 referral: Cyklo-f (tranexamic acid) [online]. Available from URL: http://www.emea.eu.int/pdfs/human/referral/090200en.pdf [Accessed 2003 Feb 14]
31. Daiichi Pharmaceutical Co. Ltd. Transamin (tranexamic acid) capsules/tablets: prescribing information [online]. Available from URL: http://www.jpma.or.jp/jpr/PDF/DAIICH05.PDF [Accessed 2003 Feb 5]
32. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996 Sep 7; 313 (7057): 579-82
33. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995 May; 102 (5): 401-6
34. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991 Mar; 164 (3): 879-83
35. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid: a double-blind trial. BMJ 1970 Oct 24; 4 (729): 214-6
36. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983 Jan; 90 (1): 78-83
37. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001 Dec 1; 99 (2): 238-43
38. Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding: clinical update on safety. Therapeutic Advances 1991; 4: 1-8
39. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid [letter]. Thromb Haemost 2001 Aug; 86 (2): 714-5
40. Farquhar CM. An evidence-based guideline for the management of heavy menstrual bleeding. N Z Med J 1999; 112 (1088): 174-7
41. Royal College of Obstetricians and Gynaecologists. The initial management of menorrhagia: evidence-based clinical guidelines no. 1. London: RCOG Press, 1998
42. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 43rd ed. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002
43. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001 Apr; 97 (4): 630-6
44. Shwayder JM. Pathophysiology of abnormal uterine bleeding. Obst Gynecol Clin N Am 2000; 27 (2): 219-34
45. Liddell H. Menorrhagia. N Z Med J 1993 Jun 23; 106 (958): 255-7
46. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999 Jun; 13 (2): 189-202
47. Mannucci PM. Hemostatic drugs. N Engl J Med 1998 Jul 23; 339 (4): 245-53
48. Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clinics for menstrual problems: an audit of general practice records. Br J Obstet Gynaecol 1991 Aug; 98 (8): 789-96
49. Garry R. Endometrial ablation and resection: validation of a new surgical concept. Br J Obstet Gynaecol 1997 Dec; 104 (12): 1329-31
50. Fraser IS. Medical, surgical and combination therapy for dysfunctional uterine bleeding. Contemporary Rev Obstet Gynecol 1999; 11 (3): 181-93
51. Okamoto S, Sato S, Takada Y, et al. An active stereo isomer (trans-form) of AMCHA and its fibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 1964; 13: 177-85
52. Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001 Jan; 108 (1): 74-86
53. Dardano KL, Burkman RT. The intrauterine contraceptive device: an often-forgotten and maligned method of contraception. Am J Obstet Gynecol 1999 Jul; 181 (1): 1-5
54. Higham JM, Shaw RW. Risk-benefit assessment of drugs used for the treatment of menstrual disorders. Drug Saf 1991 May; 6 (3): 183-91
55. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (4): CD000249
56. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2002; (1): CD000400
57. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (2): CD001016
58. Coulter A, Kelland J, Peto V, et al. Treating menorrhagia in primary care: an overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995 Summer; 11 (3): 456-71
59. Park S, Farquhar CM. A survey of practice preferences and attitudes to the New Zealand Guidelines for the Management of Heavy Menstrual Bleeding. Aust N Z J Obstet Gynaecol 2002 Oct; 42 (4): 374-8